130 related articles for article (PubMed ID: 30980254)
21. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
Gehlert DR; Shekhar A; Morin SM; Hipskind PA; Zink C; Gackenheimer SL; Shaw J; Fitz SD; Sajdyk TJ
Eur J Pharmacol; 2005 Feb; 509(2-3):145-53. PubMed ID: 15733549
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).
Vrudhula VM; Dasgupta B; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2010 Mar; 20(6):1905-9. PubMed ID: 20185312
[TBL] [Abstract][Full Text] [Related]
23. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
Valdez GR
CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
25. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.
Teleb M; Kuppast B; Spyridaki K; Liapakis G; Fahmy H
Eur J Med Chem; 2017 Sep; 138():900-908. PubMed ID: 28750312
[TBL] [Abstract][Full Text] [Related]
27. Exploring the binding site crevice of a family B G protein-coupled receptor, the type 1 corticotropin releasing factor receptor.
Gkountelias K; Papadokostaki M; Javitch JA; Liapakis G
Mol Pharmacol; 2010 Oct; 78(4):785-93. PubMed ID: 20664003
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists.
McCluskey A; Keller PA; Morgan J; Garner J
Org Biomol Chem; 2003 Oct; 1(19):3353-61. PubMed ID: 14584799
[TBL] [Abstract][Full Text] [Related]
29. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
[TBL] [Abstract][Full Text] [Related]
30. Residues remote from the binding pocket control the antagonist selectivity towards the corticotropin-releasing factor receptor-1.
Sun X; Cheng J; Wang X; Tang Y; Ågren H; Tu Y
Sci Rep; 2015 Jan; 5():8066. PubMed ID: 25628267
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.
Kojima T; Mochizuki M; Takai T; Hoashi Y; Morimoto S; Seto M; Nakamura M; Kobayashi K; Sako Y; Tanaka M; Kanzaki N; Kosugi Y; Yano T; Aso K
Bioorg Med Chem; 2018 May; 26(9):2229-2250. PubMed ID: 29459145
[TBL] [Abstract][Full Text] [Related]
32. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
33. The involvement of CRF1 receptor within the basolateral amygdala and dentate gyrus in the naloxone-induced conditioned place aversion in morphine-dependent mice.
Valero E; Gómez-Milanés I; Almela P; Ribeiro Do Couto B; Laorden ML; Milanés MV; Núñez C
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):102-114. PubMed ID: 29407532
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, in vitro biological investigation, and molecular dynamics simulations of thiazolopyrimidine based compounds as corticotrophin releasing factor receptor-1 antagonists.
Elgiushy HR; Abou-Taleb NA; Holz GG; Chepurny OG; Pirmettis I; Kakabakos S; Karageorgos V; Liapakis G; Albohy A; Abouzid KAM; Hammad SF
Bioorg Chem; 2021 Sep; 114():105079. PubMed ID: 34174633
[TBL] [Abstract][Full Text] [Related]
35. Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity.
Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
Peptides; 2005 May; 26(5):887-91. PubMed ID: 15808919
[TBL] [Abstract][Full Text] [Related]
36. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
[TBL] [Abstract][Full Text] [Related]
37. A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats.
Million M; Grigoriadis DE; Sullivan S; Crowe PD; McRoberts JA; Zhou H; Saunders PR; Maillot C; Mayer EA; Taché Y
Brain Res; 2003 Sep; 985(1):32-42. PubMed ID: 12957366
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists.
Hoare SR; Sullivan SK; Ling N; Crowe PD; Grigoriadis DE
Mol Pharmacol; 2003 Mar; 63(3):751-65. PubMed ID: 12606786
[TBL] [Abstract][Full Text] [Related]
39. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
Myers DA; Trinh JV; Myers TR
Mol Cell Endocrinol; 1998 Sep; 144(1-2):21-35. PubMed ID: 9863624
[TBL] [Abstract][Full Text] [Related]
40. Small molecule antagonists of the corticotropin releasing factor (CRF) receptor: recent medicinal chemistry developments.
Tellew JE; Luo Z
Curr Top Med Chem; 2008; 8(6):506-20. PubMed ID: 18397172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
